Lupin announces successful completion of Pithampur facility inspection by UK MHRA

Lupin Limited has announced the successful completion of the inspection carried out at its Pithampur facilities in India. The inspection was conducted from March 20 to March 24, 2023, by the UK Medicines and Healthcare products Regulatory Agency (UK MHRA). Commenting about the approval, Nilesh Gupta, Managing Director, Lupin, said “We are proud that our Pithampur site has been successfully inspected by the MHRA.

With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility and maintaining the highest standards of quality and compliance is a must.” Over the years, Lupin has grown and expanded into new areas and regions, manufacturing drugs that extend the promise of good health to communities across the globe. Beginning with two employees — a peon-cum-packer and a part-time typist — Lupin’s current global footprint spans 11 countries, across six continents. This journey has been made possible thanks to the vision and conviction of Mr. Desh Bandhu Gupta.